These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22689074)

  • 21. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells.
    Nakae S; Asano M; Horai R; Sakaguchi N; Iwakura Y
    J Immunol; 2001 Jul; 167(1):90-7. PubMed ID: 11418636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
    Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
    J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
    Richman LP; Vonderheide RH
    Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
    Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo CD40-CD154 (CD40 ligand) interaction induces integrated HIV expression by APC in an HIV-1-transgenic mouse model.
    Chougnet C; Freitag C; Schito M; Thomas EK; Sher A; Shearer GM
    J Immunol; 2001 Mar; 166(5):3210-7. PubMed ID: 11207274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
    Ye S; Cohen D; Belmar NA; Choi D; Tan SS; Sho M; Akamatsu Y; Kim H; Iyer R; Cabel J; Lake M; Song D; Harlan J; Zhang C; Fang Y; Wahl AF; Culp P; Hollenbaugh D; Chao DT
    Cancer Immunol Res; 2019 Nov; 7(11):1864-1875. PubMed ID: 31462409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
    Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigenic dietary protein guides maturation of the host immune system promoting resistance to Leishmania major infection in C57BL/6 mice.
    Amaral JF; Gomes-Santos AC; Paula-Silva J; Nicoli JR; Vieira LQ; Faria AM; Menezes JS
    Immunology; 2010 Mar; 129(3):455-64. PubMed ID: 20002788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization of chickens with an agonistic monoclonal anti-chicken CD40 antibody-hapten complex: rapid and robust IgG response induced by a single subcutaneous injection.
    Chen CH; Abi-Ghanem D; Waghela SD; Chou WK; Farnell MB; Mwangi W; Berghman LR
    J Immunol Methods; 2012 Apr; 378(1-2):116-20. PubMed ID: 22366632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells.
    Shimabukuro-Vornhagen A; Draube A; Liebig TM; Rothe A; Kochanek M; von Bergwelt-Baildon MS
    J Exp Clin Cancer Res; 2012 May; 31(1):47. PubMed ID: 22592077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40.
    Evans DE; Munks MW; Purkerson JM; Parker DC
    J Immunol; 2000 Jan; 164(2):688-97. PubMed ID: 10623811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD40-induced aggregation of MHC class II and CD80 on the cell surface leads to an early enhancement in antigen presentation.
    Clatza A; Bonifaz LC; Vignali DA; Moreno J
    J Immunol; 2003 Dec; 171(12):6478-87. PubMed ID: 14662847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
    Pandey MS; Wang C; Umlauf S; Lin S
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process.
    Mauri C; Mars LT; Londei M
    Nat Med; 2000 Jun; 6(6):673-9. PubMed ID: 10835684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice.
    Kimura K; Kakimi K; Wieland S; Guidotti LG; Chisari FV
    J Immunol; 2002 Nov; 169(9):5188-95. PubMed ID: 12391236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
    Kosaka A; Ohkuri T; Okada H
    Cancer Immunol Immunother; 2014 Aug; 63(8):847-57. PubMed ID: 24878890
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.
    von Bergwelt-Baildon MS; Vonderheide RH; Maecker B; Hirano N; Anderson KS; Butler MO; Xia Z; Zeng WY; Wucherpfennig KW; Nadler LM; Schultze JL
    Blood; 2002 May; 99(9):3319-25. PubMed ID: 11964299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells.
    Cycon KA; Clements JL; Holtz R; Fuji H; Murphy SP
    Immunology; 2009 Sep; 128(1 Suppl):e641-51. PubMed ID: 19740325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.
    Dominguez AL; Lustgarten J
    Vaccine; 2010 Feb; 28(5):1383-90. PubMed ID: 19931385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion.
    Isogawa M; Chung J; Murata Y; Kakimi K; Chisari FV
    PLoS Pathog; 2013; 9(7):e1003490. PubMed ID: 23853599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.